Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited

Critical Reviews in Oncology/Hematology

Volumn 33, Issue 1, 2000, Pages 7-23

  Hill, Bridget T ^a   Perrin, Dominique ^a   Kruczynski, Anna ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Anticancer drug; GGTase I; PFTase; Ras

Indexed keywords

1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID; 5 [N [5 (2 BENZOXAZOLYL) 1 METHYL 2 [3,4 (METHYLENEDIOXY)PHENYL] 4 PENTENYL] N (2 NAPHTHYLMETHYL)CARBAMOYL] 1,3 DIOXOLANE 2,2,4 TRICARBOXYLIC ACID; A 197574; ANTINEOPLASTIC AGENT; BIM 46068; CYCLOPHOSPHAMIDE; DIMETHYLALLYLTRANSFERASE; FLUOROURACIL; FTI 2148; GERANYLGERANYL TRANSFERASE; IRINOTECAN; LONAFARNIB; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE METHYL ESTER; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PACLITAXEL; PD 169451; PROTEIN FARNESYLTRANSFERASE; RAS PROTEIN; SCH 59228; TIPIFARNIB; UNCLASSIFIED DRUG;

CANCER THERAPY; CELL CYCLE; COLORECTAL CANCER; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PRENYLATION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN ISOPRENYLATION; RAS PROTEINS;

EID: 0033963644     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(99)00053-0     Document Type: Review

References (94)

1. Adjei A.A., Erlichman C., Davis J.N., Reid J., Sloan J., Statkevich P. et al. A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;156a.
2. Britten C.D., Rowinsky E., Yao S.-L., Soignet S., Rosen N., Eckhardt S.G. et al. The farnesyl protein transferase (FPTase) inhibitor L-778123 in patients with solid cancers. Proc. Am. Soc. Clin. Oncol. 18:1999;155a.
3. Eskens F, Awada A, Verweij J, Cutler DL, Hanauske A, Piccart. Phase I and pharmacologic study of continuous oral SCH 66336, a novel farnesyl transferase inhibitor, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 1999;18:156a.
4. Hudes G.R., Schol J., Baab J., Rogatko A., Bol C., Horak C. et al. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc. Am. Soc. Clin. Oncol. 18:1999;156a.
5. Hurwitz H.I., Colvin O.M., Petros W.P., Williams R., Conway D., Adams D.J. et al. Phase I and pharmacokinetic study of SCH666336, a novel FPTI, using a 2-week on, 2-week off schedule. Proc. Am. Soc. Clin. Oncol. 18:1999;156a.
6. Zujewski J., Horak I.D., Bol C.J.J.G., Woestenborghs R., End D., Chiao J. et al. A phase I and pharmacokinetic study of farnesyltransferase inhibitor, R115777, in advanced cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;192a.
7. Hunter T.M. Oncoprotein networks. Cell. 88:1997;779-827.
8. Cambell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., Der C. Increasing complexity of ras signalling. Oncogene. 17:1998;1395-1413.
9. Eyster K.M. Introduction to signal transduction. Biochem. Pharmacol. 55:1998;1927-1938.
10. Webb C.P., Van Aelst L., Wigler M.H., Van de Woude G.F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA. 95:1998;8773-8778.
11. Lowy D.R., Willumsen B.M. Function and regulation of Ras. Annu. Rev. Biochem. 62:1993;851-891.
12. Macara I.G., Lounsbury K.M., Richards S.A., McKiernan C., Bar-Sagi D. The Ras superfamily of GTPases. FASEB J. 10:1996;625-630.
13. Bos J.L. Ras-like GTPases. Biochim. Biophys. Acta. 1333:1997;M19-M31.
14. Bourne H., Sanders D., McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 348:1990;125-132.
15. Leonard D.M. Ras farnesyltransferase: a new therapeutic target. J. Med. Chem. 40:1997;2971-2990.
16. Wittenhoff F. Caught in the act of the switch-on. Nature. 394:1998;317-319.
17. Vojtek A.B., Der C.J. Increasing complexity of the Ras signaling pathway. J. Biol. Chem. 273:1998;19925-19928.
18. Clark G.J., Der C.J. Oncogenic activation of ras proteins. GTPases in Biology I. Dickey B.F., Birnbaumer L. Handbook of Experimental Pharmacology. 108:1993;259-288 Springer Verlag, Berlin.
19. Zachos G., Spandidos D.A. Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Crit. Rev. Oncol/Hematol. 26:1997;65-75.
20. Gibbs J.B., Graham S.L., Hartman G.D., Koblan K.S., Kohl N.E., Omer C.A. et al. Farnesyltransferase inhibitors versus Ras inhibitors. Curr. Opinion. Chem. Biol. 1:1977;197-203.
21. Jackson J.H., Cochrane C.G., Bourne J.R., Solski P.A., Buss J.E., Der C.J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA. 87:1990;3042-3046.
22. Kato K., Cox A.D., Kisaka M.M., Graham S.M., Buss J.E., Der C.J. Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA. 89:1992;6403-6407.
23. Khosravi-Far R., Solski P.A., Clark G.J., Kinch M.S., Der C.J. Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol. 15:1995;6443-6453.
24. Qiu R.-G., Chen J., Kirn D., McCormick F., Symons M. An essential role for Rac in Ras transformation. Nature. 374:1995;457-459.
25. Qiu R.-G., Chen J., McCormick F., Symons M. A role for Rho in Ras transformation. Proc. Natl. Acad. Sci. USA. 92:1995;11781-11785.
26. Gelb M.H. Protein prenylation et cetera:signal transduction in two dimensions. Science. 271:1997;1750-1751.
27. Casey P.J., Seabra M.C. Protein prenyltransferases. J. Biol. Chem. 271:1996;5289-5292.
28. Clarke S. Protein isoprenylation and methylation at carboxy-terminal cysteine residues. Annu. Rev. Biochem. 61:1992;355-386.
29. Zhang F., Casey P.J. Protein prenylation:molecular mechanisms and functional consequences. Ann. Rev. Biochem. 65:1996;241-269.
30. Clark G.J., Kinch M.S., Rogers-Graham K., Sebti S.M., Hamilton A.D., Der C.J. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 272:1997;10608-10615.
31. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras. Biochim. Biophys. Acta. 1333:1997;F51-F71.
32. Sebti S.M., Hamilton A.D. Inhibition of ras prenylation:a novel approach to cancer chemotherapy. Pharmacol. Ther. 74:1997;103-114.
33. Perrin D., Halazy S., Hill B.T. Inhibitors of the Ras signal transduction pathway as potential antitumour agents. J. Enzyme. Inhib. 11:1996;77-95.
34. Halazy S., Gotteland J.P., Lamothe M., Perrin D., Hill B.T. Rationally designed FPTase inhibitors. Drugs Future. 22:1997;1133-1146.
35. Williams T.M. Inhibitors of protein farnesylation. Exp. Opin. Ther. Patents. 8:1998;553-569.
36. Lavelle F. American Association for Cancer Research 1998; promises and prospects for the next century. Exp. Opin. Invest. Drugs. 7:1998;1015-1021.
37. Zujewski J., Horak I.D., Woestenborghs R., Chiao J., Cusak G., Kohler D. et al. Phase I trial of farnesyl-transferase inhibitor, R115777, in advanced cancer. Proc. Am. Assoc. Cancer. Res. 39:1998;270.
38. Lerner E.C., Qian Y., Hamilton A.D., Sebti S.M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltranferase I inhibitor. J. Biol. Chem. 270:1995;26770-26773.
39. Sun J., Qian Y., Hamilton A.D., Sebti S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to supress human tumor growth in nude mouse xenografts. Oncogene. 16:1998;1467-1473.
40. Rowell C.A., Kowalczyk J.J., Lewis M.D., Garcia A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272:1997;14092-14097.
41. Vasudevan A, Qian Y, Vogt A, Blaskovich M.A., Ohkanda J., Sebti S.M. et al. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J. Med. Chem. 42:1999;1333-1340.
42. Lerner EC, Zhang T-T, Knowles D.B., Qian Y, Hamilton A.D., Sebti S.M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and required both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene. 15:1997;1283-1288.
43. Kohl N.E., Mosser S.D., deSolms S.J., Giuliani E.A., Pompliano D.L., Graham S.L. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1937.
44. James GL, Goldstein JL, Brown, Rawson TE, Somers TC, McDowell RS, et al. Benzodiazepine peptidomimetics : potent inhibitors of Ras farnesylation in animal cells, Science 1993;260:1937-1942.
45. Prendergast G.C., Davide J.P., deSolms S.J., Giuliani E.A., Graham S.L., Gibbs J.B. et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14:1994;4193-4202.
46. Gibbs J.B., Oliff A. The potential of farnesyltransferase inhibitors as cancer chothapeutics. Annu. Rev. Pharmacol. Toxicol. 37:1997;143-166.
47. Lobell R.B., Kohl N.E. Pre-clinical development of farnesyltransferase inhibitors. Cancer Mets. Rev. 17:1998;203-210.
48. Lebowitz P.F., Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 17:1998;1439-1445.
49. Sepp-Lorenzino L., Ma Z., Rands E., Kohl N., Gibbs J., Oliff A. et al. Cancer Res. 55:1995;5302-5309.
50. Sepp-Lorenzino L., Rosen N. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J. Biol. Chem. 273:1998;20243-20251.
51. Kohl N.E., Wilson F.R., Mosser S.D., Giuliani E., deSolms S.J., Conner M.W. et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. 91:1994;9141-9145.
52. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolma S.J. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1:1995;792-797.
53. James G.L., Goldstein J.L., Brown M.S. Polylysine and CVIM sequences of K-RasB dictate specificity of preylation and confer resistance to benzodiazepine peptidomimetics in vitro. J. Biol. Chem. 270:1995;6221-6226.
54. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P. et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras trangenic mice. Cancer Res. 58:1998;4947-4956.
55. Zhang F.L., Kirschmeier P., Carr D., James L., Bond R.W., Wang L. et al. Characterization of Ha-Ras, N-Ras, Ki-Ras4A and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J. Biol. Chem. 272:1997;10232-10239.
56. Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I., James L., Catino J.J. et al. K- and N-Ras are geranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272:1997;14459-14464.
57. Lerner E.C., Zhang T.-T., Knowles D.B., Qian Y., Hamilton A.D., Sebti S.M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltranferase and a geranyltransferase I inhibitor in human tumor cell lines. Oncogene. 15:1997;1283-1288.
58. Perrin D, Hill BT. Tomorrow's anticancer agents : inhibitors of Ras farnesylation. In: Jolles P, editor. New Approaches to Drug Delivery. Basel:Birkhauser, Verlag AG, in press 1999.
59. McGuire T.F., Qian Y., Vogt A., Hamilton A.D., Sebti S.M. Platelet-derived growth factor receptor tyrosine phosphoylation requires protein geranylgeranylation but not farnesylation. J. Biol. Chem. 271:1996;27402-27407.
60. Miquel K., Pradines A., Sun J., Qian Y., Hamilton A.D., Sebti S.M. et al. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res. 57:1997;1846-1850.
61. Sun J., Qian Y., Chen Z., Marfurt J., Hamilton A.D., Sebti S.M. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. J. Biol. Chem. 274:1999;6930-6934.
62. Stark W.W., Blaskovich M.A., Johnson B.A., Vasudevan A., Hamilton A.D., Sebti S.M. et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am. J. Physiol. 275:1998;L55-L63.
63. Vogt A., Sun J., Qian Y., Hamilton A.D., Sebti S.M. The geranyl-geranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SD11) in a p53-independant manner. J. Biol. Chem. 272:1997;27224-27229.
64. Adnane J., Bizouarn F., Qian Y., Hamilton A.D., Sebti S.M. p21 WAF1/CIP1 is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1-responsive element: involvement of the small GTPase RhoA. Mol. Cell. Biol. 18:1998;6962-6970.
65. Lebowitz P.F., Casey P.J., Prendergast G.C., Thissen J.A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272:1997;15591-15594.
66. McGuire W.P., Hoskins W.J., Brady M.F., Kucura P.R., Partridge E.E., Look K.Y. et al. Cyclophosphamide and cisplatin with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6.
67. Olivotto I.A., Bajdik C.D., Plenderleith I.H., Coppin C.M., Gelmon K.A., Jackson S.M. et al. Adjuvant systemic therapy and survival after breast cancer. N. Engl. J. Med. 380:1994;805-810.
68. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer. An Overview of the randomised trials. Lancet 1998;352:930-942.
69. International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J. Clin. Oncol. 1997;15:1385-1394.
70. Nagasu T., Yoshimatsu K., Rowell C., Lewis M.D., Garcia A.M. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res. 55:1995;5310-5314.
71. Sun J., Qian Y., Hamilton A.D., Sebti S.M. Ras CAAX peptidomimetic FTI-276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res. 55:1995;4243-4247.
72. Waddick K.G., Uckun F.M. Innovative treatment programs against cancer. I Ras oncoprotein as a molecular target. Biochem. Pharmacol. 56:1998;1411-1426.
73. Sun J., Marfurt J., Blaskovich M.A., Bailey R.D., Qian Y., Hamilton A.D. et al. Effective combination therapy with the non-thiol farnesyltransferase inhibitor FTI-276 and taxol, gemcitabine or cisplatin for human tumor xenografts in nude mice. Proc. Am. Assoc. Cancer Res. 40:1999;522.
74. Rosenberg S.H., Alder J., Bauch J., Cherian S.P., Cohen J., Ewing P. et al. In vitro and in vivo activity of the farnesyltransferase inhibitor A-197574. Proc. Am. Assoc. Cancer Res. 40:1999;522.
75. Yonemoto M., Satoh T., Arakawa H., Suzuki-Takahashi I., Monden Y., Kodera T. et al. J-104871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner. Mol. Pharmacol. 54:1998;1-7.
76. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Li Z. et al. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother. Pharmacol. 43:1999;50-58.
77. Prevost G.P., Pradines A., Viossat I., Brezak M.-C., Lonchampt M.-O., Kasprzyk P.G. et al. Inhibition of in vitro and in vivo human cancer growth by a specific inhibitor of human farnesyl-transferase: BIM-46068. Proc. Am. Assoc. Cancer Res. 40:1999;522.
78. Smets G., Van Eyck N., Devine A., Bowden C., Wouters W., End D.W. R115777, a selective farnesyl protein transferase inhibitor (FTI), induces predominantly apoptotic activity in C32 melanoma tumor xenografts. Proc. Am. Assoc. Cancer Res. 40:1999;522.
79. Skrzat S.G., Bowden C.R., End D.W. Interaction of the farnesyl protein transferase inhibitor (FTI) R115777 with cytotoxic chemotherapeutics in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 40:1999;523.
80. Vrignaud P., Bissery M.-C., Mailliet P., Lavelle F. In vivo combination of RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor, with chemotherapy. Proc. Am. Assoc. Cancer Res. 40:1999;523.
81. Przybranowski S.A., Vincent P.W., Laithia C., Hollembaek J., Quin J., Shuler K.R. et al. In vivo evaluation of farnesyltransferase inhibitor, PD 169451, versus a panel of human tumor xenografts. Proc. Am. Assoc. Cancer Res. 39:1998;269.
82. Barrington R.E., Subler M.A., Rands E., Omer C.A., Miller P.J., Hundley J.E. et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol. 18:1998;85-92.
83. Norgaard P., Law B., Joseph H., Page D.L., Shyr Y., Mays D. et al. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF)α and TGFα/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin. Cancer Res. 5:1999;35-42.
84. Mangues R., Corral T., Kohl N.E., Symmans W.F., Lu S., Malumbres M. et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 58:1998;1253-1259.
85. Shi B., Gurnani M., Yaremko B., Lee S., Chen J., Lipari P. et al. Enhanced efficacy of the farnesyl protein transferase inhibitor SCH 66336 in combination with paclitaxel. Proc. Am. Assoc. Cancer Res. 40:1999;524.
86. Omer C.A., Chen H.Y., Conner M.W., deSolms S.J., Dinsmore C.J., Graham S.L. et al. Inhibition of tumor growth in MMTV-Kirsten-ras(Val12) transgenic mice with a farnesyl protein-transferase inhibitor. Proc. Am. Assoc. Cancer Res. 40:1999;523.
87. Moasser MM, Sepp-Lorenzine, Kohl NE, Oliff A, Balog A, Su D-S, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Nat. Acad. Sci. USA 1998;95:1369-1374.
88. Ranganathan S., McCauley R.A., Hudes G.R. Combined cell cycle and cytotoxic effects of paclitaxel and R115777, a specific inhibitor of p21 ras function and protein farnesylation in human prostate and breast carcinoma cell lines. Proc. Am. Assoc. Cancer Res. 40:1999;523.
89. Bernhard E.J., Kao G., Cox A.D., Sebti S.M., Hamilton A.D., Muschel R.J. et al. The farnesyltrasferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56:1996;1727-1730.
90. Bernhard E.J., McKenna W.G., Hamilton A.D., Sebti S.M., Qian Y., Wu J.M. et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 58:1998;1754-1761.
91. Izbicka E., Lawrence R., Davidson K., Cerna C., Gomez L., Bishop W.R. et al. Activity of a farnesyl protein transferase inhibitor (SCH 66336) against a broad range of tumors taken directly from patients. Proc. Am. Assoc. Cancer Res. 40:1999;524.
92. Peeters M., Van Cutsem E., Marse H., Plamer P., Walraven V., Willems L. Phase-I combination trial of the farnesyltransferase inhibitor (FTI) R115777 with a 5FU/LV regimen in advanced colorectal (CRC) or pancreatic (PC) cancer. Proc. Am. Soc. Clin. Oncol. 18:1999;223a.
93. Eckhardt S.G., Rizzo J., Sweeney K.R., Cropp G., Baker S.D., Kraynak M.A. et al. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J. Clin. Oncol. 17:1999;1095-1104.
94. Hudes G. Signalling inhibitors in the clinic: new agents and new challenges. J. Clin. Oncol. 17:1999;1093-1094.